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Background: Additional limus stent (Sirolimus-eluting stent [SES] and Everolimus-
eluting stent [EES]) on SES-ISR lesions has been a matter of controversy. This
prompted us to assess the clinical outcomes of additional limus stent in patients
presenting with SES-ISR comparing with balloon angioplasty.
Methods: Patients with SES-ISR undergoing repeat target lesion revascularization
(TLR) were included. We grouped the patients according to the treatment into EES,
SES, and balloon angioplasty (BA) groups. The end points were a comparison of
major adverse cardiac events (MACE) composed by all-cause mortality, myocardial
infarction (MI) and TLR, the incidence of deﬁnite stent thrombosis (ST), and the
adjusted determinants of MACE at 1 year derived by Cox multivariate analysis.
Results: Overall 308 patients [EES (n¼41), SES (n¼102) and BA (n¼165)] were
treated for SES-ISR. The baseline patient characteristics were similar between 3
groups. The incidence of MACE in the EES, SES and BA groups were 14.6%, 18%,
20%; respectively (3 way p¼0.72). The incidence of ST was 0% in all the groups. The
adjusted determinants of MACE at 1 year were acute MI as SES-ISR presentation,
number of treated lesions, diabetes mellitus, past MI history. (Table)
Conclusion: The incidence of MACE in patients with SES-ISR was not statistically
different between an additional limus stent implantation (EES or SES) and balloon
angioplasty. Additionally, MI as SES-ISR presentation was the strongest determinant
of MACE at 1 year.Multivariate analyses for predictors of 1-year MACE.HR 95% CI P valueSES (compare to EES) 1.37 0.45-4.16 0.58POBA (compare to EES) 1.64 0.55-4.86 0.37Acute MI as SES-ISR presentation 3.11 1.26-7.68 0.014Number of treated lesions 1.57 1.07-2.30 0.020Diabetes mellitus 1.85 1.04-3.27 0.036Past MI history 1.86 1.03-3.37 0.040CRT-502
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Background: Previous studies show that drug-eluting stent (DES) in-stent restenosis
(ISR) is a recurrent phenomenon. We aimed to assess the clinical outcomes of second-
generation everolimus-eluting stent (EES) in patients presenting with different DES-
ISR types.
Methods: Patients were grouped according to the everolimus (EES), paclitaxel
(PES) and sirolimus (SES) eluting stents failure at the index procedure. The end point
were the incidence of major adverse cardiac events (MACE: all-cause mortality,
myocardial infarction [MI], or target lesion revascularization [TLR]), and deﬁnite
stent thrombosis (ST). A Cox model was built to determine the predictors of MACE
at 1 year.Results: A total of 121 patients [EES (n¼29), PES (n¼26) and SES (n¼66)] un-
derwent TLR for DES-ISR were included. The baseline clinical and angiographic
parameters were comparable between the groups. The incidence of MACE at 1 year
was not statistically different between the groups (19.2% vs. 19.0% vs. 18.6%, 3 way
p¼1.0); respectively. No cases of ST occurred. The univariate predictors of MACE
were: diabetes mellitus, past MI history, ﬁrst ISR episode, and number of treated
lesions. (Table)
Conclusions: The second generation EES equalizes the clinical outcome among
different stent ISR types (limus or paclitaxel) with no ST up to 1 year. Apparently, the
ﬁrst ISR episode has a more benign proﬁle compared with recurrent ISR. This
ﬁndings encourages the use of second generation EES as a default strategy for the ﬁrst
ISR episode.Univariate analysis for predictors of 1-year MACE.HR 95% CI p valuePES failure (compare to EES failure) 0.95 0.26-3.54 0.94SES failure (compare to EES failure) 0.91 0.30-2.77 0.86Diabetes Mellitus 3.13 1.02-9.62 0.046Past MI history 3.22 1.12-9.26 0.030First ISR episode 0.31 0.11-0.88 0.027Number of lesions treated 2.14 1.13-4.05 0.020Science
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